These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36628320)

  • 1. How reliable are ICER's results published in current pharmacoeconomic literature? The controversial issue of price confidentiality.
    Russo P
    Glob Reg Health Technol Assess; 2022; 9():31-35. PubMed ID: 36628320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports.
    Ronquest NA; Paret K; Gould IG; Barnett CL; Mladsi DM
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1601-1612. PubMed ID: 34714108
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service.
    Russo P; Zanuzzi M; Carletto A; Sammarco A; Romano F; Manca A
    Pharmacoeconomics; 2023 Jan; 41(1):107-117. PubMed ID: 36434415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey.
    Russo P; Carletto A; Németh G; Habl C
    Health Policy; 2021 Sep; 125(9):1140-1145. PubMed ID: 34253396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments?
    Cohen JT; Silver MC; Ollendorf DA; Neumann PJ
    Value Health; 2019 Dec; 22(12):1396-1401. PubMed ID: 31806196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of Value-Based Price for 48 High-Technology Medical Devices.
    Hyeraci G; Trippoli S; Rivano M; Messori A
    Cureus; 2023 Jun; 15(6):e39934. PubMed ID: 37287820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands.
    Heine RJSD; Mathijssen RHJ; Verbeek FAJ; Van Gils C; Uyl-de Groot CA
    Value Health; 2024 Oct; 27(10):1367-1372. PubMed ID: 38909683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.
    Xoxi E; Rumi F; Kanavos P; Dauben HP; Gutierrez-Ibarluzea I; Wong O; Rasi G; Cicchetti A
    Front Med Technol; 2022; 4():888404. PubMed ID: 35782579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Research Groups Align on an Intervention's Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders.
    Sussman M; Yu JC; Menzin J
    Appl Health Econ Health Policy; 2020 Aug; 18(4):477-489. PubMed ID: 31919779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.
    Schöttler MH; Coerts FB; Postma MJ; Boersma C; Rozenbaum MH
    Value Health; 2023 Jan; 26(1):91-98. PubMed ID: 35933271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic Review of Health State Utility Values Used in European Pharmacoeconomic Evaluations for Chronic Hepatitis C: Impact on Cost-Effectiveness Results.
    Han R; François C; Toumi M
    Appl Health Econ Health Policy; 2021 Jan; 19(1):29-44. PubMed ID: 32661846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need.
    Dionne PA; Ali F; Grobler M
    J Health Econ Outcomes Res; 2015; 3(1):13-23. PubMed ID: 34430665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confidentiality agreements: a challenge in market regulation.
    Iunes RF; Uribe MV; Torres JB; Garcia MM; Dias CZ; Alvares-Teodoro J; de Assis Acurcio F; Guerra-Junior AA
    Int J Equity Health; 2019 Jun; 18(1):11. PubMed ID: 31155003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of early phase price agreements on prices of orphan drugs.
    Nuijten M; Van Wilder P
    BMC Health Serv Res; 2021 Mar; 21(1):222. PubMed ID: 33711994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.